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ABSTRACT
Background. The management of breast cancer (BC) skin
metastases represents a therapeutic challenge. Elec-
trochemotherapy (ECT) combines the administration of
bleomycin with temporary permeabilization induced by
locally administered electric pulses. Preliminary experi-
ence with ECT in BC patients is encouraging.
Methods. A total of 125 patients with BC skin metastases
who underwent ECT between 2010 and 2013 were enrolled
onto a multicenter retrospective cohort study. The treat-
ment was administered following the European Standard
Operative Procedures of Electrochemotherapy. Tumor
response was clinically assessed adapting the Response
Evaluation Criteria in Solid Tumors, and toxicity was
evaluated according to Common Terminology Criteria for
Adverse Events 4.0. Cox regression analysis was used to
identify predictive factors.
Results. Response was evaluable in 113 patients for 214
tumors (median 1 per patient, range 1–3). The overall
response rate after 2 months was 90.2 %, while the com-
plete response (CR) rate was 58.4 %. In multivariate
analysis, small tumor size (P\ 0.001), absence of visceral
metastases (P = 0.001), estrogen receptor positivity
(P = 0.016), and low Ki-67 index (P = 0.024) were sig-
nificantly associated with CR. In the first 48 h, 10.4 % of
patients reported severe skin pain. Dermatologic toxicity
included grade 3 skin ulceration (8.0 %) and grade 2 skin
hyperpigmentation (8.8 %). Tumor 1-year local progres-
sion-free survival was 86.2 % (95 % confidence interval
79.3–93.8) and 96.4 % (95 % confidence interval 91.6–
100) in the subgroup of those with CR.
Conclusions. In this study, small tumor size, absence of
visceral metastases, estrogen receptor positivity, and low Ki-
67 index were predictors of CR after ECT. Patients who
experienced CR had durable local control. ECT represents a
valuable skin-directed therapy for selected patients with BC.
Skin metastases from breast cancer (BC) are often
symptomatic for ulceration, bleeding, and pain, and they
may represent a challenge for clinicians, particularly in
heavily pretreated patients. Surgical resection, radiother-
apy, and systemic therapies can be variously combined
according to individual patient characteristics, tumor fea-
tures, and physician choice.1 When surgical excision is not
possible, radiotherapy ensures sustained local control, even
if this is not feasible in preirradiated areas.2 Systemic
therapies, such as endocrine treatment, chemotherapy, and
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targeted agents, represent valuable options, depending on
the molecular subtype of BC and prior therapies.3 Appli-
cation of topic chemotherapy and laser ablation is limited
to cancers confined to the top layer of skin.4 Elec-
trochemotherapy (ECT) combines the administration of a
poorly permeant cytotoxic agent, such as bleomycin
(BLM), with the local application of electric pulses that
induce reversible electroporation, thus improving drug
diffusion into cells.5 ECT was introduced in 2006,
demonstrating a high rate of efficacy and favorable toxicity
profile in a European multicenter study on skin metastases
from different tumor histotypes.6 In this study, the objec-
tive response (OR) rate on treated tumor nodules was
89.0 % with complete regression in 73.3 % of cases. A
recently published meta-analysis including 47 prospective
studies comparing five skin-directed therapies (ECT, radi-
ation, photodynamic therapy, intralesional therapy, and
topical therapy), ECT demonstrated an OR rate of 75.4 %
(CR rate, 47.5 %) with a low toxicity profile (grade 3 in
less than 6 % of patients).7 In this analysis, melanoma and
BC comprised 96.8 % of all cutaneous metastases, with
similar response rates.
To our knowledge, published data on ECT in BC
patients with cutaneous skin metastases are based on small,
single-center, heterogeneous series. Consequently, these
series do not allow for identification of clinical and/or
biologic factors that are reliably predictive of ECT
response.8 The aim of our study was to provide a systemic
analysis on a large series of BC patients treated with ECT,
evaluating potential predictive factors of response to
treatment.
PATIENTS AND METHODS
Patients
Between January 2010 and June 2013, the Italian
Senological Group for Electrochemotherapy (GISEL),
involving 13 Italian institutions, performed this multicenter
retrospective cohort study. Inclusion criteria for ECT
included BC patients with cutaneous and/or subcutaneous
histologically confirmed metastases. Exclusion criteria for
ECT included tumors in close proximity to a cardiac
pacemaker; allergy to BLM; prior cumulative dose of BLM
exceeding 250,000 IU/m2; serum creatinine[150 lmol/L;
lung fibrosis; and pregnancy or lactation. Patients were
enrolled regardless of the presence of other metastases. The
respective institutional review boards of the participating
institutions approved the study. All patients gave informed
consent for the procedure and for utilization of their data
for scientific purposes. Clinical records were anonymously
entered into a dedicated encrypted online database.
Evaluation of Estrogen Receptor (ER), Progesterone
Receptor (PgR), HER2 Status, and Ki-67 Index
Histologic diagnosis, immunohistochemical analysis,
and fluorescence in situ hybridization for HER2 gene
amplification (in case of inconclusive results on HER2
status) were performed according to international guide-
lines. The cutoff for ER and PgR positivity was 1 % of
cells with positive nuclear staining.9 Positivity for HER2
was determined by either immunohistochemistry 3? or
fluorescence in situ hybridization amplification. The cutoff
point for the Ki-67 labeling index was 14 %.10 Surrogate
subtypes were defined according to the criteria established
by the St. Gallen International Breast Cancer Conference.11
Treatment
The European Standard Operative Procedures of Elec-
trochemotherapy (ESOPE) were used for all patients.12
Accordingly, the dose and route of BLM administration
were adapted to the number and size of tumors in case of
intratumoral injection, and to the patient’s body surface
area in case of intravenous infusion. The procedure was
scheduled in a day-hospital regimen, and patients were
usually discharged after an observation period of 24 h.
Patient Assessment
Patients were evaluated after 1 and 2 weeks for acute
toxicity and at 4 and 8 weeks for late toxicity and tumor
response; subsequent follow-up visits were planned every
3–4 months. Among 125 patients, 12 (9.6 %) were fol-
lowed for less than 2 months after ECT and were not
considered for assessment of response.
For each patient, up to a maximum of five measurable
tumors were registered as target lesions. The sum of their
maximum diameters represented the baseline measurement
for assessment of tumor response, which was clinically
performed by Response Evaluation Criteria in Solid
Tumors 1.1.13 In case of the presence of many confluent
nodules, when it was impossible to count their exact
number, they were considered as a single entity and mea-
sured as a single area of treatment. Treatment toxicity and
adverse events were graded according to the Common
Terminology Criteria for Adverse Events 4.14 Pain was
graded according to a 0–10 numeric pain intensity scale
(0 = no pain, 10 = maximum pain).15
Statistical Analysis
In descriptive analyses, continuous variables are repor-
ted as median value and interquartile range and categorical
variables are reported as absolute number and percentage.
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Evaluation of tumor response was performed by con-
tingency tables and Pearson’s v2 test.
Survival curves were estimated by the Kaplan–Meier
method and compared to the log rank test. Hazard ratios
were calculated by a Cox proportional risk model, after
proportional hazard assumption confirmation with
Schoenfeld residuals. Local progression-free survival
(LPFS) was calculated from achievement of response in the
treated area to local progression of disease, including the
appearance of new nodules in the same area, or last follow-
up. Statistical analyses were performed by SPSS 22.0
(IBM) software.
RESULTS
Patient and Disease Characteristics
Baseline patient and disease characteristics are reported
in Table 1. The prevalent tumor histotype was infiltrating
ductal carcinoma (76.6 %). Tumor, node, metastasis clas-
sification of primary BC was T1–T2 in 48 % patients and
T3–T4 in 52 %; 67.2 % patients had lymph node
involvement, and 22.4 % had distant metastases.
The median number of target lesions was 1 (range 1–3),
with a median size of 21 mm (range 15–45 mm). The
overwhelming majority of lesions—222 (92.9 %) of 239—
were localized on the chest wall.
Forty-one patients (32.8 %) received chemotherapy in a
neoadjuvant setting at the time of primary BC, while 62
patients (49.6 %) underwent chemotherapy in an adjuvant
setting. Seventy-one patients (56.8 %) received adjuvant
endocrine treatment. All patients had received at least one
previous systemic treatment for metastatic disease. Specifi-
cally, 39 patients (31.2 %) received chemotherapy (median
of two lines of treatment, range 1–6) and 69 patients received
endocrine therapy (median two lines of treatment, range 1–
3). Fifty-three patients (42.4 %) underwent adjuvant radio-
therapy and 15 patients (12.0 %) were irradiated for the
presence of skin metastases. As a result, 92 (38.5 %) of 239
target lesions in the present study were located in preirradi-
ated skin. There were more previous systemic treatments in
patients with triple negative (median 3, range 1–7) andHER2
positive (median 3, range 2–6) BC than in patients with
luminal A-like (median 1, range 0–6), luminal B-like (me-
dian 2, range 0–6), and luminal B-like, HER2-positive
tumors (median 2, range 0–5, P = 0.042).
Treatment
In 92 (73.6 %) of 125 patients, ECT was administered
under general anesthesia or sedation, while local anesthesia
was used in the remaining 33 patients (26.4 %). BLM was
administered intravenously in 100 patients (80.0 %) and
intratumorally in 25 (20.0 %). Of 239 tumors, 207
(86.6 %) were electroporated with a hexagonal-array nee-
dle electrode, 10 (4.2 %) with a linear-row needle
electrode, 13 (5.4 %) with a plate electrode, and 9 (3.8 %)
with multiple electrode types.
Toxicity
No serious adverse events were reported during the
procedure.
TABLE 1 Patient characteristics (n = 125)
Characteristic Median (range)
or n (%)
Age (years) 63 (54–72)
Histology
IDC 97 (76.6)
Non-IDC 28 (23.4)
Time since occurrence of skin metastases (mo) 32 (9–109)
Skin metastases (n = 239)
No. per patient 1 (1–3)
Size (mm) 21 (15–45)
Location
Chest 222 (92.9)
Other site 17 (7.1)
Skin condition
Previous radiotherapy 92 (38.5)
Lymphedema 30 (12.6)
Ulceration 64 (26.8)
Immunohistochemistry
ER positive 72 (57.6)
PgR positive 72 (57.6)
HER2 overexpression 35 (28.0)
Ki-67\ 14 % 63 (50.4)
Surrogate subtypesa
Luminal A-like 23 (18.4)
Luminal B-like (HER2 negative) 22 (17.6)
Luminal B-like (HER2 positive) 18 (14.4)
Triple negative 35 (28)
HER2 11 (8.8)
Previous treatmentsb
Radiotherapy 68 (54.4)
Chemotherapy 92 (73.6)
Endocrine therapy 71 (56.8)
Targeted therapy 14 (11.2)
Surgery for skin metastases 89 (71.2)
IDC invasive ductal carcinoma, ER estrogen receptor, PR proges-
terone receptor
a Assessed on 113 patients, according to St. Gallen consensus11
b Any setting
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Toxicity data reported within the first 2 months are
presented in Table 2. Paracetamol and nonsteroidal anti-
inflammatory agents were effective in controlling post-
procedural pain in all but four patients, who required
narcotics, although as a single administration. The inci-
dence of skin ulceration did not differ significantly
depending on previous radiation (41.3 % of previous skin
radiations vs. 30 % no previous skin radiation, P = 0.436).
After the first ECT, 96 patients were asked if they would
agree to receive another course of treatment, if required,
and 96.9 % declared that they were potentially favorable.
Tumor Response
Among 125 patients, the follow-up of 12 (9.6 %) was less
than 2 months after ECT; these subjects were not evaluated
for response. Therefore, 113 (90.4 %) of 125 patients and
214 (89.5 %) of 239 target lesions were evaluated for tumor
response. Two months after ECT, per-tumor response was as
follows: CR 68.5 %, partial response (PR) 23.5 %, stable
disease 6.6 %, progressive disease 0.9 %, and not evaluable
0.5 % as a result of inflammatory reaction and crust forma-
tion. Accordingly, the OR rate was 92 % (Fig. 1).
Sixty-six patients (58.4 %) experienced CR, 36
(31.8 %) PR, 8 (7.1 %) stable disease, and 2 (1.8 %) had
progressive disease; in 1 patient (0.9 %), tumor response
was not evaluable as a result of local skin conditions.
Overall, the per-patient OR rate was 90.2 %.
The variables associated with response are shown in
Table 3. The CR rate was higher in small (\3 cm) rather
than large (C3 cm) tumors (80.3 vs. 46.1 %, P\ 0.0001)
and in patients without visceral metastases rather than in
those with visceral involvement (80.5 vs. 55.0 %,
P\ 0.001). The CR rate was also higher among ER-pos-
itive (77.2 vs. 59.8 % in ER-negative, P = 0.006) and low
proliferating tumors (Ki-67\ 14 %, 79.5 % vs. Ki-
67[ 14 %, 58.8 %; P\ 0.001). In multivariate analysis,
tumor size\3 cm was confirmed to be the most powerful
predictor of CR (P\ 0.001), followed by the absence of
visceral metastases (P = 0.001), ER-positive status
(P = 0.016), and low Ki-67 (P = 0.024).
The distribution of tumor response according to the BC
intrinsic subtypes is presented in Table 4. The CR rate in
patients with luminal A-like disease was significantly
higher compared to all other subgroups (73.9 vs. 54.7 %,
P = 0.02). There was no significant difference in tumor
size among BC subtypes (P = 0.262).
There was no significant association between response
and several clinical (patient age, P = 1.00; type of surgery
on primary BC, P = 0.070; time from primary BC to
recurrence, P = 0.269; presence of lymphedema,
P = 0.636; previous radiation, P = 1.00) and procedural
(anesthesiology technique, P = 0.377; electrode type,
P = 0.799; route of BLM administration, P = 0.606;
number of electric pulses, P = 0.842) parameters.
Local Tumor Control
Median follow-up time was 5.9 months (range 3–
58 months). Median LPFS was not reached. One-year
LPFS was 86.2 % (95 % confidence interval [CI] 79.3–
93.8) (Fig. 2).
One-year LPFS in patients who experienced a CR was
96.4 % (95 % CI 91.6–100). In multiple Cox regression
analysis, tumor size was the only significant prognostic
factor for LPFS (Table 3).
One-year LPFS survival in patients with small (\3 cm)
tumors was 97.4 % (95 % CI 92.6–100), whereas in those
with larger tumors (C3 cm), it was 75.6 % (95 % CI 63.9–
83.4 P = 0.005).
TABLE 2 Toxicity within 2 months after electrochemotherapy (n = 125)
Toxicity Any grade, n (%) Grade 1, n (%) Grade 2, n (%) Grade 3, n (%)
Skin pain 79 (63.2) 28 (22.4) 38 (30.4) 13 (10.4)
Skin ulceration 41 (32.8) 17 (13.6) 14 (11.2) 10 (8.0)
Skin hyperpigmentation 34 (27.2) 23 (18.4) 11 (8.8) –
Body odor 10 (8) 4 (3.2) 6 (4.8) –
Nausea 10 (8) 10 (8) 0 (0) 0 (0)
Skin infection 9 (7.2) 6 (4.8) 2 (1.6) 1 (0.8)
Flulike symptoms 8 (6.4) 8 (6.4) 0 (0) 0 (0)
Fever 7 (5.6) 7 (5.6) 0 (0) 0 (0)
Rash 5 (4) 1 (0.8) 4 (3.2) 0 (0)
Soft tissue infection 2 (1.6) 0 (0) 2 (1.6) 0 (0)
Vomiting 2 (1.6) 2 (1.6) 0 (0) 0 (0)
Localized edema 1 (0.8) 0 (0) 1 (0.8) 0 (0)
Postoperative hemorrhage 1 (0.8) 0 (0) 1 (0.8) 0 (0)
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DISCUSSION
This study showed for the first time that a subgroup of
BC patients, identified by routinely used immunohisto-
chemical markers, was particularly sensitive to ECT with
BLM. To our knowledge, this cohort analysis was based on
the largest series of BC patients treated by ECT to date.
ECT was mainly administered under general sedation or
general anesthesia (74 % of patients), while the preferential
route for BLM administration was intravenous infusion
(80 % of patients). In most cases (89 %), treated tumors
were managed using a hexagonal-array, 20 mm long nee-
dle electrode. The most frequently reported adverse effects
were transient pain and dermatologic toxicity.16–22 Gen-
erally, treated skin develops a transient inflammatory
reaction. Occasionally, erosions or ulcerations may occur,
followed by crust formation. In case of tumor regression,
the skin may appear slightly less pigmented, while in some
patients it is possible to observe local skin hyperpigmen-
tation, which is a well-known effect of BLM. In patients
with locally advanced disease, tumor shrinkage after ECT
may cause tissue ulceration requiring specialist wound
care.22 Nevertheless, previous experience has demonstrated
that effective management of cutaneous metastases
provided symptomatic relief and better quality of life to
patients.20
With the present study, we confirm the absence of sys-
temic adverse effects of ECT, as well as a favorable
toxicity profile (grade 3 ulceration in 8 % of patients,
according to the meta-analysis of Spratt et al., grade 2
hyperpigmentation in 8.8 %), and a high level of accep-
tance.7 Patients experienced minimal discomfort and
needed small amounts of postprocedural analgesics; fur-
ther, only 10 % of adverse effects were severe, with the
exception of transient pain within the first 48 h. As a result,
97 % of the 96 patients who were asked if they would
agree to receive further treatment responded favorably. Our
results are in line with the ESOPE study, where more than
90 % of patients declared that they were potentially
amenable to treatment.6
Melanoma and BC represented more than 95 % of
tumors included in two recently published meta-analyses
where the indicated CR rates after ECT were 59 and
57.5 %, respectively.7,23 In the present study, the OR rate
was 90.2 %, with a CR rate of 58.4 %, in agreement with
the ESOPE study which reported an OR rate of 90.4 %,
with 64.3 % of patients experiencing CR.6 A recently
published clinical trial on 55 patients, representing the
FIG. 1 Skin metastases from BC treated with ECT in two patients. Baseline presentation (a, c) and 1-year follow-up (b, d). Arrows contour
tumor spread or indicate skin metastases
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largest published retrospective experience with ECT in BC,
showed a CR response rate of 40 % as the most favorable
outcome among elderly patients.22 Consistent with a recent
meta-analysis, in the present study the response to treat-
ment in small tumors (\3 cm) was higher, similar to that
seen in ER-positive, low-proliferating tumors (representing
the luminal A-like BC subtype) and in patients without
ulcerated lesions or visceral metastases.24
In particular, the CR rate in the luminal A-like BC
subtype was 73.9 %, which was significantly higher than in
triple-negative and HER2 positive BC patients (57.1 and
54.5 %, respectively), independent of tumor size. How-
ever, although ECT in triple-negative BC in our series was
used after failure of several lines of treatment and in con-
ditioning a highly refractory disease, the CR rate in this
group nonetheless exceeded 50 %.
We are aware that clinical evaluation may be a subjec-
tive assessment of tumor response. A pilot study including
11 patients with chest wall recurrence from BC
investigated the role of 18F-fludeoxyglucose positron
emission tomography (FDG-PET). This study indicates
that not only FDG-PET/computed tomography (CT) but
also dual time point imaging FDG-PET/CT is promising
for evaluation and planning of ECT and could be useful for
other localized anticancer treatments as well.25 On the
other hand, this imaging technique, which is not widely
available and which has nonnegligible costs, has a low
sensitivity for small tumor deposits, limiting its application
in cutaneous oncology.26
In our patients, data on local control indicated a 1-year
LPFS of 86.2 % within the ECT field (Fig. 2), increasing to
96.4 % in those with CR. In our experience, small (\3 cm)
tumor size represented the main predictor of local control
compared to large (C3 cm) tumor size (97.4 vs. 75.6 % at
1 year, respectively).
Skin involvement represents a less frequent but not
uncommon event in the metastatic pattern of BC, accounting
for 5–30 % of advanced cases in different series.1,2 In
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TABLE 4 Tumor response to electrochemotherapy according to surrogate definition of breast cancer intrinsic subtypes
Response Luminal A-like
(n = 23), n (%)
Luminal B-like (HER2
negative) (n = 22), n (%)
Luminal B-like (HER2
positive) (n = 18), n (%)
Triple negative
(n = 35), n (%)
HER2 positive
(n = 11), n (%)
CR 17 (73.9) 11 (50.0) 10 (55.6) 20 (57.1) 6 (54.5)
PR 4 (17.4) 9 (40.9) 5 (27.8) 11 (31.4) 5 (45.5)
SD 1 (4.3) 2 (9.1) 1 (5.6) 4 (11.4) 0 (0)
PD 1 (4.3) 0 (0) 1 (5.6) 0 (0) 0 (0)
NA 0 (0) 0 (0) 1 (5.6) 0 (0) 0 (0)
According to Goldhirsh et al.11; n = 109 (in four patients, there was no reliable pathologic information). Luminal A-like tumors (ER and PgR
positive, HER2 negative, Ki-67 low); luminal B-like, HER2-negative tumors (ER positive, HER2 negative, Ki-67 high and/or PgR low or
negative); luminal B-like, HER2 positive tumors (ER positive, HER2 overexpressed or amplified); HER2 positive, nonluminal tumors (HER2
overexpressed or amplified, ER and PgR negative); triple negative tumors (ER, PgR, and HER2 negative)
CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessable, ER estrogen receptor, PR progesterone
receptor
Breast Cancer Metastases and Electrochemotherapy
addition to their association with unfavorable prognosis, skin
metastases cause strong psychologic distress.16 Surgical
resection with a radical intent can only be offered to a limited
number of patients as a result of multifocality and clinically
occult lymphangitic spread.27 In these cases, radiotherapy is
generally the best option, but it is often unfeasible on pre-
viously irradiated tissues and on lesions that have spread on a
wide area. Lack of capillary distribution of radiologic
facilities in the territory and the long duration of the entire
cycle on multiple sessions may represent further criticisms.
Conversely, ECT is applicable on preirradiated areas with
the possibility to treat many lesions in a single session,
without systemic side effects and a favorable toxicity profile.
At any rate, ECT is repeatable and can even be performed in
an outpatient setting.
Undoubtedly, our findings need broader and prospective
confirmation. Furthermore, it will be necessary to clarify
whether delaying progression of cutaneous metastases by
ECT may provide clinically meaningful benefit to patients,
such as delay of disease-related symptoms or preservation
of quality of life. In general, the value of progression-free
survival, as a surrogate marker for patient benefit, has
recently been subjected to critical reappraisal.28 In fact,
patient-centered outcomes will a crucial issue in future
studies on ECT.29,30
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